Trifluridine/tipiracil + oxaliplatin ± nivolumab vs FOLFOX ± nivolumab in HER2 negative advanced oesogastric adenocarcinoma: The PRODIGE73-UCGI40-LOGICAN trial
Digestive and Liver Disease · 2024
DOI: 10.1016/j.dld.2024.04.032 ↗Kurz gefasst
Fachartikel in der Zeitschrift Digestive and Liver Disease, 2024. Verfasst von Damien Botsen und 25 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Godinot Cancer Institute, 1 avenue General Koenig, Reims 51100, France. Hauptthemen laut MEDLINE: Adenocarcinoma, Antineoplastic Combined Chemotherapy Protocols, Drug Combinations, Esophagogastric Junction. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: Trifluridine/tipiracil (FTD/TPI) is approved in third-line treatment of patients with advanced/metastatic gastric and gastroesophageal junction adenocarcinomas (aGA/GEJA). The association of oxaliplatin with FTD/TPI is promising and the combination of FTD/TPI + oxaliplatin + nivolumab has shown a predictable and manageable safety profile. AIMS: The aim is to evaluate the efficacy and safety of FTD/TPI plus oxaliplatin with or without nivolumab in patients, with HER2 negative aGA/GEJA, unfit for triplet chemotherapy (TFOX/mFLOT regimen), in the first-line metastatic setting in comparison with the standard of care FOLFOX with or without nivolumab. METHODS: This study is a prospective randomised, open label, comparative, multicentre, phase II trial designed to include 118 patients. The primary objective is to evaluate the superiority of FTD/TPI plus oxaliplatin with or without nivolumab over FOLFOX regimen with or without nivolumab in terms of PFS in a population of patients non candidate for triplet chemotherapy. Nivolumab will be used for patients whose tumour express PD-L1 with a CPS score ≥5. DISCUSSION: PRODIGE73-UCGI40-LOGICAN study will provide efficacy and safety data on the association of FTD/TPI plus oxaliplatin with or without nivolumab versus FOLFOX regimen with or without nivolumab in first-line palliative setting, in patients with aGA/GEJA (NCT05476796).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Oncology Department, Godinot Cancer Institute, 1 avenue General Koenig, Reims 51100, France.
- Department of Clinical Research and Innovation, Centre Léon Bérard, Lyon, France.
- Medical Oncology Department, Saint-Joseph Hospital, Marseille, France.
- Medical Oncology Department, Beauvais Hospital, Beauvais, France.
- Clinique Pasteur Lanroze, Brest, France.
- Gastroenterology Department, Villefranche Sur Saone North West Hospital, Gleize, France.
Zitieren
APA
Botsen, D., Chabaud, S., Perrier, H., Ammarguellat, H., Jestin-Le-Tallec, V., Olesinski, J., Toullec, C., Aparicio, T., Ben Abdelghani, M., Borg, C., Bouche, O., Coutzac, C., Devaud, H., Di Fiore, F., Dubreuil, O., Evesque, L., Huguenin, B., Muller, M., Poureau, P. G., …, & De La Fouchardiere, C. (2024). Trifluridine/tipiracil + oxaliplatin ± nivolumab vs FOLFOX ± nivolumab in HER2 negative advanced oesogastric adenocarcinoma: The PRODIGE73-UCGI40-LOGICAN trial. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2024.04.032
Vancouver
Botsen D, Chabaud S, Perrier H, Ammarguellat H, Jestin-Le-Tallec V, Olesinski J, et al. Trifluridine/tipiracil + oxaliplatin ± nivolumab vs FOLFOX ± nivolumab in HER2 negative advanced oesogastric adenocarcinoma: The PRODIGE73-UCGI40-LOGICAN trial. Digestive and Liver Disease. 2024. doi:10.1016/j.dld.2024.04.032
BibTeX
@article{Botsen2024,
author = {Botsen, Damien and Chabaud, Sylvie and Perrier, Hervé and Ammarguellat, Hanifa and Jestin-Le-Tallec, Véronique and Olesinski, Jonathan and Toullec, Clémence and Aparicio, Thomas and Ben Abdelghani, Meher and Borg, Christophe and Bouche, Olivier and Coutzac, Clélia and Devaud, Hervé and Di Fiore, Frédéric and Dubreuil, Olivier and Evesque, Ludovic and Huguenin, Bruno and Muller, Marie and Poureau, Pierre-Guillaume and Oularue, Emilie and Tougeron, David and Zaanan, Aziz and Ammari, Samy and De Sousa Carvalho, Nicolas and Decazes, Pierre and De La Fouchardiere, Christelle},
title = {Trifluridine/tipiracil + oxaliplatin ± nivolumab vs FOLFOX ± nivolumab in HER2 negative advanced oesogastric adenocarcinoma: The PRODIGE73-UCGI40-LOGICAN trial},
journal = {Digestive and Liver Disease},
year = {2024},
doi = {10.1016/j.dld.2024.04.032}
}
EUVIMED